OKYO Pharma’s Lead Asset, OK-101, Receives USAN Designation as “Urcosimod”
OKYO Pharma Ltd, a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for various ophthalmic diseases, made an exciting announcement on [Current Date]. The company revealed that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) “urcosimod” by the United States Adopted Names Council (USANC). This designation is a significant milestone in the development of OK-101 as a potential treatment for unmet medical needs in ophthalmology.
Progress in Developing Treatments for Neuropathic Corneal Pain and Inflammatory Dry Eye Disease
The USAN designation for OK-101 as “urcosimod” reinforces OKYO Pharma’s progress in developing treatments for conditions such as neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). NCP is a chronic and debilitating condition characterized by pain in the cornea, which can significantly impact a patient’s quality of life. DED, on the other hand, is a common condition that affects millions of people worldwide, causing symptoms such as dryness, redness, and discomfort in the eyes.
Impact on Patients
For patients suffering from NCP and DED, the development of urcosimod as a potential treatment represents a promising advancement. Current treatment options for these conditions are often inadequate, and many patients experience limited relief from their symptoms. Urcosimod, which is a selective small molecule modulator of the transient receptor potential vanilloid 1 (TRPV1) ion channel, has shown promise in clinical trials for its ability to alleviate pain and inflammation in the eye. The USAN designation brings us one step closer to making this treatment available to those who need it.
Impact on the World
Beyond the individual patient level, the development of urcosimod as a potential treatment for NCP and DED has the potential to make a significant impact on the world. According to the National Eye Institute, an estimated 5 million Americans have DED, and up to 25% of the population may experience NCP at some point in their lives. The economic burden of these conditions is substantial, with direct and indirect costs estimated to be in the billions of dollars annually. A safe and effective treatment for NCP and DED could significantly reduce the burden on patients and healthcare systems alike.
Conclusion
The USAN designation of OK-101 as “urcosimod” is an important step forward for OKYO Pharma and the field of ophthalmology. This designation reinforces the potential of urcosimod as a treatment for neuropathic corneal pain and inflammatory dry eye disease, conditions that currently have limited treatment options. For patients, this means the possibility of relief from debilitating symptoms and improved quality of life. For the world, it represents a potential solution to the significant economic burden of these conditions. As the development of urcosimod continues, we look forward to seeing the positive impact it may have on the lives of those affected by NCP and DED.
- OKYO Pharma’s lead asset, OK-101, receives USAN designation as “urcosimod”
- Designation reinforces progress in developing treatments for NCP and DED
- Urcosimod is a selective small molecule modulator of the TRPV1 ion channel
- Potential treatment for debilitating conditions with limited options
- Could significantly reduce the economic burden of NCP and DED
